Across TCGA pan-cancer cohorts, GFUS Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GFUS data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher GFUS Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GFUS expression acts as an unfavorable survival marker.
SARC, UCEC, and PRAD are the cancer types where GFUS Mutation most reproducibly stratifies survival.